Mecasermin

From WikiProjectMed
Jump to navigation Jump to search
Mecasermin
Names
Trade namesIncrelex
Other namesFK-780; recombinant human insulin-like growth factor-1; rhIGF-1; somatomedin-1
Clinical data
Main usesGrowth failure due to primary insulin-like growth factor-I deficiency[1]
Side effectsHeadache, low blood sugar, vomiting, lump at the site of injection, middle ear infection[2]
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
use
Subcutaneous injection
Typical dose0.04 to 0.12 mg/kg BID[2]
External links
AHFS/Drugs.comMonograph
US NLMMecasermin
Legal
License data
Legal status
Pharmacokinetics
Elimination half-life5.8 hours[3]
Chemical and physical data
FormulaC331H512N94O101S7
Molar mass7648.71 g·mol−1

Mecasermin, sold under the brand name Increlex, is medication used to treat growth failure in children due to primary insulin-like growth factor-I deficiency or lack of the gene for growth hormone.[1] It is also being look at for amyotrophic lateral sclerosis.[1] It is given by injection under the skin.[1]

Common side effects include headache, low blood sugar, vomiting, lump at the site of injection, and middle ear infection.[2] Other side effects may include enlarged tonsils, intracranial hypertension, and slipped capital femoral epiphysis.[1] It is a recombinant form of human insulin-like growth factor-1 (rhIGF-1).[1]

Mecasermin was approved for medical use in the United States in 2005 and Europe in 2007.[1][2] In the United States 400 mg costs about 54,000 USD as of 2021.[4] This amount in the United Kingdom costs the NHS about £24,000.[5]

Medical uses

It may be used in those 2 to 18 years old.[2]

Dosage

It is started at 0.04 mg/kg twice per day and may be increased up to 0.12 mg/kg twice per day.[2]

Chemistry

Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[3]

A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[6] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[6]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Mecasermin Monograph for Professionals". Drugs.com. Archived from the original on 6 March 2021. Retrieved 14 November 2021.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 "Increlex". Archived from the original on 14 November 2021. Retrieved 15 November 2021.
  3. 3.0 3.1 "INCRELEX® (mecasermin [rDNA origin] injection) Highlights of Prescribing Information" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 2021-04-03. Retrieved 2020-08-23.
  4. "Increlex Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 15 November 2021.
  5. "Mecasermin". NICE. Archived from the original on 15 November 2021. Retrieved 15 November 2021.
  6. 6.0 6.1 "IPLEXTM (mecasermin rinfabate [rDNA origin] injection) Package Insert" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 2020-10-30. Retrieved 2020-08-23.

External links

External sites:
Identifiers: